Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations

Orbital Scintigraphy with the Somatostatin Receptor Tracer 99mTc-P829 in Patients with Graves’ Disease

Georg Burggasser, Ingrid Hurtl, Wolfgang Hauff, Julius Lukas, Michaela Greifeneder, Bamdad Heydari, Arnulf Thaler, Andreas Wedrich and Irene Virgolini
Journal of Nuclear Medicine October 2003, 44 (10) 1547-1555;
Georg Burggasser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid Hurtl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Hauff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julius Lukas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michaela Greifeneder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bamdad Heydari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnulf Thaler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Wedrich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Virgolini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Receptors for somatostatin (SST) (SSTR) are expressed on various tumor cells as well as on activated lymphocytes. Previous data have shown that 99mTc-P829 binds with high affinity to many different types of tumor cells as well as to leukocytes via the human hSSTR2, hSSTR3, and hSSTR5 target receptors. Consequently, 99mTc-P829 was successfully introduced as a peptide tracer for tumor imaging. In this study, we evaluated the orbital uptake of 99mTc-P829 in patients with active and inactive thyroid-associated orbitopathy (TAO), accompanied by lymphocyte infiltration in the acute stage and by muscle fibrosis in the chronic stage of the disease. Methods: To evaluate its clinical usefulness in Graves’ disease, 99mTc-P829 scintigraphy (≈740 MBq) was performed in 44 patients with TAO (median duration, 19 mo; range, 1–360 mo). The clinical activity of the orbital disease was graded by the NOSPECS (no signs or symptoms; only signs, no symptoms; signs only; proptosis; eye muscle involvement; corneal involvement; sight visual acuity reduction) classification of the American Thyroid Association, the clinical activity score (CAS), and the superonasal index (SNI). SPECT (360°) and planar studies were completed within 3 h after injection. Orbital (O) regions of interest (ROIs) were compared with temporoparietal and occipital (OCC) ROIs. Orbital uptake ratios in Graves’ disease were compared with data obtained from lung cancer patients with no eye disease (n = 22). Results: Overall, 99mTc-P829 biokinetics were the same in Graves’ disease patients as in lung cancer patients, showing a rapid blood clearance and visualization of the facial bones within minutes of injection. In all control patients, the orbit appeared as a “cold area,” whereas visual orbital accumulation of 99mTc-P829 was found in patients with active TAO (O/OCC ratios: 1.26 ± 0.04 vs. 1.69 ± 0.04; P < 0.01, respectively). Patients with active eye disease (n = 25) presented with an increased orbital uptake of 99mTc-P829 compared with patients with inactive disease (n = 19; O/OCC ratio: 1.12 ± 0.05; P < 0.01). A statistically significant correlation was found between CAS and the orbital uptake (O/OCC ratio) values (r = 0.90), whereas no correlation could be documented regarding the NOSPECS classification as well as the SNI. Conclusion: In TAO, 99mTc-P829 yields high orbital binding with good clinical correlation. The better image quality due to the high energy of technetium, the lower radiation dose for patients and personnel, and the short acquisition protocol favor SSTR scintigraphy with 99mTc-P829 over 111In-labeled compounds. The in-house availability of the radiotracer and cost-effectiveness are further advantages.

  • somatostatin receptor
  • somatostatin receptor imaging
  • 99mTc-P829
  • 99mTc-NeoSpect
  • 99mTc-NeoTect
  • Graves’
  • disease
  • thyroid associated orbitopathy

Footnotes

  • Received Oct. 31, 2002; revision accepted May 20, 2003.

    For correspondence or reprints contact: Georg Burggasser, MD, Department of Ophthalmology and Optometry, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

    E-mail: georg.burggasser{at}akh-wien.ac.at

View Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 44, Issue 10
October 1, 2003
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Orbital Scintigraphy with the Somatostatin Receptor Tracer 99mTc-P829 in Patients with Graves’ Disease
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Orbital Scintigraphy with the Somatostatin Receptor Tracer 99mTc-P829 in Patients with Graves’ Disease
Georg Burggasser, Ingrid Hurtl, Wolfgang Hauff, Julius Lukas, Michaela Greifeneder, Bamdad Heydari, Arnulf Thaler, Andreas Wedrich, Irene Virgolini
Journal of Nuclear Medicine Oct 2003, 44 (10) 1547-1555;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Orbital Scintigraphy with the Somatostatin Receptor Tracer 99mTc-P829 in Patients with Graves’ Disease
Georg Burggasser, Ingrid Hurtl, Wolfgang Hauff, Julius Lukas, Michaela Greifeneder, Bamdad Heydari, Arnulf Thaler, Andreas Wedrich, Irene Virgolini
Journal of Nuclear Medicine Oct 2003, 44 (10) 1547-1555;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire